-
AstraZeneca's Tagrisso Scores Approval In China For Early Lung Cancer
Wednesday, April 14, 2021 - 9:16am | 191Read More...AstraZeneca Plc (NASDAQ: AZN) said that China’s health regulator had expanded the use of Tagrisso in patients with a type of lung cancer when diagnosed at an early stage. China’s National Medical Products Administration (NMPA) approved Tagrisso as adjuvant therapy...
-
Karyopharm's Partner Antengene Receives Priority Review For Selinexor Application In China
Wednesday, February 24, 2021 - 8:09am | 179Read More...Karyopharm Therapeutics Inc's (NASDAQ: KPTI) collaborating partner Antengene Corporation Limited has received priority review from China's National Medical Products Administration (NMPA) for ATG-010 (selinexor, XPOVIO). It is a first-in-class selective...
